PubMed:23246576
Annnotations
PubMed_Structured_Abstracts
Id | Subject | Object | Predicate | Lexical cue |
---|---|---|---|---|
T1 | 156-545 | BACKGROUND | denotes | Chemotherapeutic drug resistance remains a clinical obstacle in cancer management. Drug-resistant cancer cells usually exhibit cross-resistance to ionizing radiation, which has devastating consequences for patients. With a better understanding of the molecular mechanisms, it will be possible to develop strategies to overcome this cross-resistance and to increase therapeutic sensitivity. |
T2 | 555-1078 | METHODS | denotes | Natural and synthetic flavonoid compounds including xanthohumol, the principal flavonoid in hops, were investigated for its radio-sensitizing activity on human breast cancer MCF-7 and adriamycin-resistant MCF-7 (MCF-7/ADR) cells. Chemo-sensitizing or radio-sensitizing effect was analyzed by tetrazolium-based colorimetric assay and flow cytometry. Western blot analysis, confocal microscopy, gene silencing with siRNA transfection and luciferase reporter gene assay were performed to examine signaling molecule activation. |
T3 | 1088-1835 | RESULTS | denotes | Among the tested flavonoid compounds, pretreatment of the cells with xanthohumol significantly sensitized MCF-7/ADR cells to the radiation treatment by inducing apoptosis. In MCF-7/ADR cells, treatment with xanthohumol alone or with gamma-rays significantly decreased levels of anti-apoptotic proteins. Multi-drug resistance 1 (MDR1), epidermal growth factor receptor (EGFR) and signal transducer and activator of transcription 3 (STAT3) expression levels in MCF-7/ADR cells were suppressed by xanthohumol treatment. In addition, xanthohumol treatment increased death receptor (DR)-4 and DR5 expression. The xanthohumol-induced changes of these resistance-related molecules in MCF-7/ADR cells were synergistically increased by gamma-ray treatment. |
T4 | 1849-1940 | CONCLUSIONS | denotes | Xanthohumol restored sensitivity of MCF-7/ADR cells to doxorubicin and radiation therapies. |
T5 | 1963-2108 | CONCLUSIONS | denotes | Our results suggest that xanthohumol may be a potent chemo- and radio-sensitizer, and its actions are mediated through STAT3 and EGFR inhibition. |
sentences
Id | Subject | Object | Predicate | Lexical cue |
---|---|---|---|---|
TextSentencer_T1 | 0-143 | Sentence | denotes | The radio-sensitizing effect of xanthohumol is mediated by STAT3 and EGFR suppression in doxorubicin-resistant MCF-7 human breast cancer cells. |
TextSentencer_T2 | 144-155 | Sentence | denotes | BACKGROUND: |
TextSentencer_T3 | 156-238 | Sentence | denotes | Chemotherapeutic drug resistance remains a clinical obstacle in cancer management. |
TextSentencer_T4 | 239-371 | Sentence | denotes | Drug-resistant cancer cells usually exhibit cross-resistance to ionizing radiation, which has devastating consequences for patients. |
TextSentencer_T5 | 372-545 | Sentence | denotes | With a better understanding of the molecular mechanisms, it will be possible to develop strategies to overcome this cross-resistance and to increase therapeutic sensitivity. |
TextSentencer_T6 | 546-554 | Sentence | denotes | METHODS: |
TextSentencer_T7 | 555-784 | Sentence | denotes | Natural and synthetic flavonoid compounds including xanthohumol, the principal flavonoid in hops, were investigated for its radio-sensitizing activity on human breast cancer MCF-7 and adriamycin-resistant MCF-7 (MCF-7/ADR) cells. |
TextSentencer_T8 | 785-903 | Sentence | denotes | Chemo-sensitizing or radio-sensitizing effect was analyzed by tetrazolium-based colorimetric assay and flow cytometry. |
TextSentencer_T9 | 904-1078 | Sentence | denotes | Western blot analysis, confocal microscopy, gene silencing with siRNA transfection and luciferase reporter gene assay were performed to examine signaling molecule activation. |
TextSentencer_T10 | 1079-1087 | Sentence | denotes | RESULTS: |
TextSentencer_T11 | 1088-1259 | Sentence | denotes | Among the tested flavonoid compounds, pretreatment of the cells with xanthohumol significantly sensitized MCF-7/ADR cells to the radiation treatment by inducing apoptosis. |
TextSentencer_T12 | 1260-1390 | Sentence | denotes | In MCF-7/ADR cells, treatment with xanthohumol alone or with gamma-rays significantly decreased levels of anti-apoptotic proteins. |
TextSentencer_T13 | 1391-1604 | Sentence | denotes | Multi-drug resistance 1 (MDR1), epidermal growth factor receptor (EGFR) and signal transducer and activator of transcription 3 (STAT3) expression levels in MCF-7/ADR cells were suppressed by xanthohumol treatment. |
TextSentencer_T14 | 1605-1691 | Sentence | denotes | In addition, xanthohumol treatment increased death receptor (DR)-4 and DR5 expression. |
TextSentencer_T15 | 1692-1835 | Sentence | denotes | The xanthohumol-induced changes of these resistance-related molecules in MCF-7/ADR cells were synergistically increased by gamma-ray treatment. |
TextSentencer_T16 | 1836-1848 | Sentence | denotes | CONCLUSIONS: |
TextSentencer_T17 | 1849-1940 | Sentence | denotes | Xanthohumol restored sensitivity of MCF-7/ADR cells to doxorubicin and radiation therapies. |
TextSentencer_T18 | 1941-1962 | Sentence | denotes | GENERAL SIGNIFICANCE: |
TextSentencer_T19 | 1963-2108 | Sentence | denotes | Our results suggest that xanthohumol may be a potent chemo- and radio-sensitizer, and its actions are mediated through STAT3 and EGFR inhibition. |
T1 | 0-143 | Sentence | denotes | The radio-sensitizing effect of xanthohumol is mediated by STAT3 and EGFR suppression in doxorubicin-resistant MCF-7 human breast cancer cells. |
T2 | 144-155 | Sentence | denotes | BACKGROUND: |
T3 | 156-238 | Sentence | denotes | Chemotherapeutic drug resistance remains a clinical obstacle in cancer management. |
T4 | 239-371 | Sentence | denotes | Drug-resistant cancer cells usually exhibit cross-resistance to ionizing radiation, which has devastating consequences for patients. |
T5 | 372-545 | Sentence | denotes | With a better understanding of the molecular mechanisms, it will be possible to develop strategies to overcome this cross-resistance and to increase therapeutic sensitivity. |
T6 | 546-554 | Sentence | denotes | METHODS: |
T7 | 555-784 | Sentence | denotes | Natural and synthetic flavonoid compounds including xanthohumol, the principal flavonoid in hops, were investigated for its radio-sensitizing activity on human breast cancer MCF-7 and adriamycin-resistant MCF-7 (MCF-7/ADR) cells. |
T8 | 785-903 | Sentence | denotes | Chemo-sensitizing or radio-sensitizing effect was analyzed by tetrazolium-based colorimetric assay and flow cytometry. |
T9 | 904-1078 | Sentence | denotes | Western blot analysis, confocal microscopy, gene silencing with siRNA transfection and luciferase reporter gene assay were performed to examine signaling molecule activation. |
T10 | 1079-1087 | Sentence | denotes | RESULTS: |
T11 | 1088-1259 | Sentence | denotes | Among the tested flavonoid compounds, pretreatment of the cells with xanthohumol significantly sensitized MCF-7/ADR cells to the radiation treatment by inducing apoptosis. |
T12 | 1260-1390 | Sentence | denotes | In MCF-7/ADR cells, treatment with xanthohumol alone or with gamma-rays significantly decreased levels of anti-apoptotic proteins. |
T13 | 1391-1604 | Sentence | denotes | Multi-drug resistance 1 (MDR1), epidermal growth factor receptor (EGFR) and signal transducer and activator of transcription 3 (STAT3) expression levels in MCF-7/ADR cells were suppressed by xanthohumol treatment. |
T14 | 1605-1691 | Sentence | denotes | In addition, xanthohumol treatment increased death receptor (DR)-4 and DR5 expression. |
T15 | 1692-1835 | Sentence | denotes | The xanthohumol-induced changes of these resistance-related molecules in MCF-7/ADR cells were synergistically increased by gamma-ray treatment. |
T16 | 1836-1848 | Sentence | denotes | CONCLUSIONS: |
T17 | 1849-1940 | Sentence | denotes | Xanthohumol restored sensitivity of MCF-7/ADR cells to doxorubicin and radiation therapies. |
T18 | 1941-1962 | Sentence | denotes | GENERAL SIGNIFICANCE: |
T19 | 1963-2108 | Sentence | denotes | Our results suggest that xanthohumol may be a potent chemo- and radio-sensitizer, and its actions are mediated through STAT3 and EGFR inhibition. |
DisGeNET
Id | Subject | Object | Predicate | Lexical cue |
---|---|---|---|---|
T0 | 69-73 | gene:1956 | denotes | EGFR |
T1 | 123-136 | disease:C0006142 | denotes | breast cancer |
T2 | 69-73 | gene:1956 | denotes | EGFR |
T3 | 123-136 | disease:C0678222 | denotes | breast cancer |
R1 | T0 | T1 | associated_with | EGFR,breast cancer |
R2 | T2 | T3 | associated_with | EGFR,breast cancer |
Allie
Id | Subject | Object | Predicate | Lexical cue |
---|---|---|---|---|
SS1_23246576_12_0 | 1391-1414 | expanded | denotes | Multi-drug resistance 1 |
SS2_23246576_12_0 | 1416-1420 | abbr | denotes | MDR1 |
SS1_23246576_12_1 | 1423-1455 | expanded | denotes | epidermal growth factor receptor |
SS2_23246576_12_1 | 1457-1461 | abbr | denotes | EGFR |
SS1_23246576_12_2 | 1467-1517 | expanded | denotes | signal transducer and activator of transcription 3 |
SS2_23246576_12_2 | 1519-1524 | abbr | denotes | STAT3 |
SS1_23246576_13_0 | 1650-1664 | expanded | denotes | death receptor |
SS2_23246576_13_0 | 1666-1668 | abbr | denotes | DR |
AE1_23246576_12_0 | SS1_23246576_12_0 | SS2_23246576_12_0 | abbreviatedTo | Multi-drug resistance 1,MDR1 |
AE1_23246576_12_1 | SS1_23246576_12_1 | SS2_23246576_12_1 | abbreviatedTo | epidermal growth factor receptor,EGFR |
AE1_23246576_12_2 | SS1_23246576_12_2 | SS2_23246576_12_2 | abbreviatedTo | signal transducer and activator of transcription 3,STAT3 |
AE1_23246576_13_0 | SS1_23246576_13_0 | SS2_23246576_13_0 | abbreviatedTo | death receptor,DR |
PubmedHPO
Id | Subject | Object | Predicate | Lexical cue |
---|---|---|---|---|
T1 | 220-226 | HP_0002664 | denotes | cancer |
T2 | 254-260 | HP_0002664 | denotes | cancer |
DisGeNET5_gene_disease
Id | Subject | Object | Predicate | Lexical cue |
---|---|---|---|---|
23246576-0#69#73#gene1956 | 69-73 | gene1956 | denotes | EGFR |
23246576-0#123#136#diseaseC0006142 | 123-136 | diseaseC0006142 | denotes | breast cancer |
23246576-0#123#136#diseaseC0678222 | 123-136 | diseaseC0678222 | denotes | breast cancer |
69#73#gene1956123#136#diseaseC0006142 | 23246576-0#69#73#gene1956 | 23246576-0#123#136#diseaseC0006142 | associated_with | EGFR,breast cancer |
69#73#gene1956123#136#diseaseC0678222 | 23246576-0#69#73#gene1956 | 23246576-0#123#136#diseaseC0678222 | associated_with | EGFR,breast cancer |
DisGeNet-2017-sample
Id | Subject | Object | Predicate | Lexical cue |
---|---|---|---|---|
T2606 | 69-73 | gene:1956 | denotes | EGFR |
T2607 | 123-136 | disease:C0006142 | denotes | breast cancer |
R1 | T2606 | T2607 | associated_with | EGFR,breast cancer |
R2 | T2606 | T2607 | associated_with | EGFR,breast cancer |
UBERON-AE
Id | Subject | Object | Predicate | Lexical cue |
---|---|---|---|---|
PD-UBERON-AE-B_T1 | 123-129 | http://purl.obolibrary.org/obo/UBERON_0000310 | denotes | breast |
PD-UBERON-AE-B_T2 | 715-721 | http://purl.obolibrary.org/obo/UBERON_0000310 | denotes | breast |
performance-test
Id | Subject | Object | Predicate | Lexical cue |
---|---|---|---|---|
PD-UBERON-AE-B_T1 | 123-129 | http://purl.obolibrary.org/obo/UBERON_0000310 | denotes | breast |
PD-UBERON-AE-B_T2 | 715-721 | http://purl.obolibrary.org/obo/UBERON_0000310 | denotes | breast |
mondo_disease
Id | Subject | Object | Predicate | Lexical cue | mondo_id |
---|---|---|---|---|---|
T1 | 123-136 | Disease | denotes | breast cancer | http://purl.obolibrary.org/obo/MONDO_0007254 |
T2 | 220-226 | Disease | denotes | cancer | http://purl.obolibrary.org/obo/MONDO_0004992 |
T3 | 244-260 | Disease | denotes | resistant cancer | http://purl.obolibrary.org/obo/MONDO_0036501 |
T4 | 715-728 | Disease | denotes | breast cancer | http://purl.obolibrary.org/obo/MONDO_0007254 |
NCBITAXON
Id | Subject | Object | Predicate | Lexical cue | db_id |
---|---|---|---|---|---|
T1 | 117-122 | OrganismTaxon | denotes | human | 9606 |
T2 | 709-714 | OrganismTaxon | denotes | human | 9606 |
Anatomy-UBERON
Id | Subject | Object | Predicate | Lexical cue | uberon_id |
---|---|---|---|---|---|
T1 | 123-129 | Body_part | denotes | breast | http://purl.obolibrary.org/obo/UBERON_0000310 |
T2 | 715-721 | Body_part | denotes | breast | http://purl.obolibrary.org/obo/UBERON_0000310 |
T3 | 1423-1439 | Body_part | denotes | epidermal growth | http://purl.obolibrary.org/obo/UBERON_0000021 |